

CORRECTION

[View Article Online](#)
[View Journal](#) | [View Issue](#)

 CrossMark
 click for updates

Cite this: RSC Adv., 2015, 5, 34910

Correction: Sustainable construction: admicellar catalysed synthesis of pyrimido[4,5-*b*]quinolines in an aqueous system

 I. R. Siddiqui,^{*a} Pragati Rai,^a Rahila,^a Hoezyfa Sagir^a and Prashant Singh^b

DOI: 10.1039/c5ra90037a

 Correction for 'Sustainable construction: admicellar catalysed synthesis of pyrimido[4,5-*b*]quinolines in an aqueous system' by I. R. Siddiqui *et al.*, RSC Adv., 2015, 5, 27603–27609.

The characterization data of compounds **4a–4l** in the Experimental section of the paper is incorrect. The correct characterization data is given below. (Part of this data was previously available as electronic supplementary information (ESI). No additional ESI exists for this work.)

5-(4-Chlorophenyl)benzo[G]pyrimido[4,5-*b*]quinoline-2,4,6,11(1*h*,3*h*,5*h*,12*h*)-tetraone (**4a**)

Orange powder; mp 294 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3315, 3244, 1726, 1651, 1596, 1543. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 5.09 (s, 1H, CH), 7.28 (d, $J_{\text{HH}} = 8.4$ Hz, 2H), 7.37 (d, $J_{\text{HH}} = 8.5$ Hz, 2H), 7.77–8.04 (m, 4H, H-Ar), 9.39 (s, 1H, NH), 10.22 (s, 1H, NH), 10.95 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 35.0, 90.1, 118.9, 126.8, 126.9, 128.7, 130.8, 131.5, 132.6, 132.9, 134.3, 135.8, 139.6, 144.5, 148.7, 151.2, 164.4, 179.8, 182.5. MS (EI, 70 eV): m/z (%): 405 (M⁺, 10), 371 (10), 325 (45), 234 (28), 156 (26), 77 (78), 57 (80), 43 (100). For C₂₁H₁₂ClN₃O₄ (405.79): C, 62.16; H, 2.98; N, 10.36; found: C, 62.25; H, 2.85; N, 10.49.

5-(4-Bromophenyl)benzo[G]pyrimido[4,5-*b*]quinoline-2,4,6,11(1*h*,3*h*,5*h*,12*h*)-tetraone (**4b**)

Orange powder; mp 299 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3406, 3249, 3054, 1735, 1661, 1605, 1577. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 5.14 (s, 1H, CH), 6.91–7.99 (m, 8H, H-Ar), 9.34 (s, 1H, NH), 10.18 (s, 1H, NH), 10.86 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 36.7, 87.9, 119.8, 125.4, 126.8, 126.9, 129.9, 131.6, 132.3, 134.7, 135.9, 138.8, 149.1, 154.8, 159.3, 163.9, 181.4, 184.7. MS (EI, 70 eV): m/z (%): 449 (M⁺, 8), 371 (12), 373 (50), 278 (30), 156 (22), 76 (80), 57 (80), 43 (100). For C₂₁H₁₂BrN₃O₄ (450.24): C, 56.02; H, 2.69; N, 9.33; found: C, 56.19; H, 2.57; N, 14.34.

5-(4-Nitrophenyl)benzo[G]pyrimido[4,5-*b*]quinoline-2,4,6,11(1*h*,3*h*,5*h*,12*h*)-tetraone (**4c**)

Red powder; mp 297 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3358, 3240, 3073, 1719, 1684, 1631, 1577. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 5.25 (s, 1H, CH), 7.36 (d, $J_{\text{HH}} = 8.5$ Hz, 2H), 7.48 (d, $J_{\text{HH}} = 8.5$ Hz, 2H), 7.73–8.14 (m, 4H, H-Ar), 9.31 (s, 1H, NH), 10.20 (s, 1H, NH), 10.83 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 37.2, 88.0, 119.3, 126.8, 126.9, 128.7, 131.0, 131.2, 132.1, 132.8, 134.7, 136.2, 138.9, 145.0, 151.3, 160.1, 163.5, 181.8, 183.6. MS (EI, 70 eV): m/z (%): 416 (M⁺, 15), 371 (16), 340 (54), 245 (34), 156 (18), 76 (84), 57 (76), 43 (100). For C₂₁H₁₂N₄O₆ (416.34): C, 60.58; H, 2.91; N, 13.46; found: C, 60.72; H, 2.85; N, 13.51.

5-Phenylbenzo[G]pyrimido[4,5-*b*]quinoline-2,4,6,11(1*h*,3*h*,5*h*,12*h*)-tetraone (**4d**)

Red powder; mp 300 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3411, 3250, 3065, 1717, 1645, 1608, 1561. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 5.22 (s, 1H, CH), 7.11–8.11 (m, 9H, H-Ar), 9.29 (s, 1H, NH), 10.11 (s, 1H, NH), 10.82 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 35.6, 86.7, 119.6, 124.4, 126.6, 126.8, 127.9, 128.9, 131.6, 132.4, 134.4, 135.7, 139.8, 151.2, 155.7, 159.3, 163.4, 181.8, 185.6. MS (EI, 70 eV): m/z (%): 371 (M⁺, 5), 328 (12), 295 (42), 200 (30), 156 (22), 76 (80), 43 (100). For C₂₁H₁₃N₃O₄ (371.35): C, 67.92; H, 3.53; N, 11.32; found: C, 68.06; H, 3.51; N, 11.46.

^aLaboratory of Green Synthesis, Department of Chemistry, University of Allahabad, Allahabad-211002, India. E-mail: dr.irsiddiqui@gmail.com

^bNanotechnology Application Centre, University of Allahabad, Allahabad, 211002, India



5-m-Tolylbenzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4e)

Red powder; mp 282 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3327, 3268, 3050, 1723, 1657, 1610, 1529. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 2.71 (s, 3H, Me), 5.25 (s, 1H, CH), 7.03–8.15 (m, 8H, H-Ar), 9.24 (s, 1H, NH), 10.16 (s, 1H, NH), 10.89 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 24.5, 35.5, 86.6, 117.6, 124.0, 126.4, 127.0, 127.4, 128.0, 128.7, 131.4, 132.5, 134.1, 135.4, 135.7, 138.1, 139.9, 152.5, 161.2, 163.3, 182.9, 183.8. MS (EI, 70 eV): m/z (%): 385 (M⁺, 8), 294 (40), 214 (22), 156 (28), 91 (70), 57 (78), 43 (100). For C₂₂H₁₅N₃O₄ (385.37): C, 68.57; H, 3.92; N, 10.90; found: C, 68.71; H, 3.86; N, 10.85.

5-o-Tolylbenzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4f)

Red powder; mp 277 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3417, 3248, 3055, 1714, 1657, 1609, 1533. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 2.77 (s, 3H, Me), 5.17 (s, 1H, CH), 7.01–8.04 (m, 8H, H-Ar), 9.31 (s, 1H, NH), 10.17 (s, 1H, NH), 10.87 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 22.2, 35.6, 86.8, 117.1, 124.0, 126.3, 126.9, 127.5, 127.9, 128.7, 131.3, 132.6, 134.2, 135.3, 135.4, 138.0, 139.1, 151.2, 158.1, 163.8, 182.4, 183.3. MS (EI, 70 eV): m/z (%): 385 (M⁺, 10), 309 (44), 214 (26), 156 (20), 91 (74), 57 (82), 43 (100). For C₂₂H₁₅N₃O₄ (385.37): C, 68.57; H, 3.92; N, 10.90; O, 16.61; found: C, 68.80; H, 3.76; N, 10.92.

5-p-Tolylbenzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4g)

Red powder; mp 311 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3408, 3253, 3059, 1717, 1656, 1608, 1517. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 2.19 (s, 3H, Me), 5.07 (s, 1H, CH), 7.02 (d, $J_{\text{HH}} = 7.7$ Hz, 2H), 7.19 (d, $J_{\text{HH}} = 7.7$ Hz, 2H), 7.79–8.04 (m, 4H, H-Ar), 9.21 (s, 1H, NH), 10.14 (s, 1H, NH), 10.89 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 21.2, 35.4, 86.5, 114.6, 126.5, 126.8, 129.2, 130.5, 130.9, 131.4, 132.5, 134.4, 135.8, 138.7, 144.5, 148.8, 159.1, 163.4, 179.9, 183.2. MS (EI, 70 eV): m/z (%): 385 (M⁺, 5), 294 (45), 214 (30), 156 (20), 76 (78), 57 (82), 43 (100). For C₂₂H₁₅N₃O₄ (385.37): C, 68.57; H, 3.92; N, 10.90; found: C, 68.51; H, 3.86; N, 10.80.

5-(4-Methoxyphenyl)benzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4h)

Orange powder; mp 301 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3423, 3178, 3057, 1704, 1681, 1611, 1533. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 3.64 (s, 3H, OMe), 5.03 (s, 1H, CH), 6.76 (d, $J_{\text{HH}} = 7.7$ Hz, 2H, H-Ar), 7.21 (d, $J_{\text{HH}} = 7.6$ Hz, 2H, H-Ar), 7.81–8.02 (m, 4H, H-Ar), 9.32 (s, 1H, NH), 10.16 (s, 1H, NH), 10.91 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 32.5, 56.7, 86.5, 114.9, 124.5, 126.2, 126.9, 129.7, 130.0, 130.5, 133.9, 133.1, 133.7, 135.4, 138.0, 144.7, 159.1, 163.6, 179.7, 183.1. MS (EI, 70 eV): m/z (%): 401 (M⁺, 15), 358 (14), 325 (30), 230 (26), 156 (22), 57 (76), 43 (100). For C₂₂H₁₅N₃O₅ (401.37): C, 65.83; H, 3.77; N, 10.47; found: C, 65.88; H, 3.74; N, 10.58.

5-(4-Chlorophenyl)-1,3-dimethylbenzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4i)

Orange powder; mp 251 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3402, 1716, 1654, 1580, 1517. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 3.19 (s, 3H, NMe), 3.36 (s, 3H, NMe), 5.66 (s, 1H, CH), 7.10–7.88 (m, 8H, H-Ar), 13.11 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 29.7, 31.4, 35.3, 86.2, 118.9, 124.0, 126.8, 126.9, 130.4, 131.2, 131.6, 132.6, 134.4, 135.1, 138.9, 150.1, 155.1, 156.4, 164.1, 181.6, 186.9. MS (EI, 70 eV): m/z (%): 433 (M⁺, 5), 322 (8), 271 (30), 235 (100), 156 (72), 76 (82), 57 (26). For C₂₃H₁₆ClN₃O₄ (433.84): C, 63.67; H, 3.72; Cl, 8.17; N, 9.69; found: C, 63.83; H, 3.54; N, 8.29.

5-(4-Bromophenyl)-1,3-dimethylbenzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4j)

Orange powder; mp 229 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3398, 1705, 1656, 1575, 1511. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 3.11 (s, 3H, NMe), 3.37 (s, 3H, NMe), 5.81 (s, 1H, CH), 7.18–7.91 (m, 8H, H-Ar), 13.12 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 29.2, 32.3, 35.3, 89.0, 119.4, 124.1, 126.7, 127.0, 131.0, 131.2, 131.6, 132.4, 134.6, 135.6, 139.1, 151.0, 155.3, 156.4, 164.5, 181.8, 186.7. MS (EI, 70 eV): m/z (%): 477 (M⁺, 5), 338 (22), 321 (32), 235 (100), 156 (76), 76 (80). For C₂₃H₁₆BrN₃O₄ (478.29): C, 57.76; H, 3.37; N, 8.79; found: C, 57.87; H, 3.36; N, 8.84.

1,3-Dimethyl-5-p-tolylbenzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4k)

Red powder; mp 263 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3359, 1720, 1657, 1568. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 2.27 (s, 3H, Me), 3.11 (s, 3H, NMe), 3.33 (s, 3H, NMe), 5.52 (s, 1H, CH), 6.99 (d, $J_{\text{HH}} = 7.8$ Hz, H-Ar), 7.21 (d, $J_{\text{HH}} = 7.9$ Hz, H-Ar), 7.77–8.06 (m, 4H, H-Ar), 9.04 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 22.8, 28.9, 31.7, 36.6, 88.7, 116.1, 124.4, 126.4, 126.8, 128.9, 130.8, 131.5, 134.5, 135.5, 135.7, 136.9, 139.4, 151.1, 158.1, 163.4, 181.7, 184.6. MS (EI, 70 eV): m/z (%): 413 (M⁺, 10), 322 (6), 275 (20), 235 (100), 156 (72), 76 (80). For C₂₄H₁₉N₃O₄ (413.43): C, 69.72; H, 4.63; N, 10.16; found: C, 69.79; H, 4.46; N, 10.20.

1,3-Dimethyl-5-m-tolylbenzo[G]pyrimido[4,5-b]quinoline-2,4,6,11(1h,3h,5h,12h)-tetraone (4l)

Red powder; mp 195 °C. IR (KBr) ($\nu_{\text{max}}/\text{cm}^{-1}$): 3327, 1705, 1656, 1569, 1529. ^1H NMR (400 MHz, DMSO-d₆): δ_{H} (ppm) 2.24 (s, 3H, Me), 3.17 (s, 3H, NMe), 3.38 (s, 3H, NMe), 5.82 (s, 1H, CH), 6.94–8.01 (m, 8H, H-Ar), 13.02 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO-d₆): δ_{C} (ppm) 22.5, 29.9, 31.2, 35.6, 86.8, 111.9, 124.7, 126.6, 127.0, 127.3, 128.2, 128.8, 131.5, 132.7, 134.3, 135.4, 135.3, 137.9, 139.2,



151.2, 155.3, 164.5, 181.8, 184.4. MS (EI, 70 eV): m/z (%): 413 (M^+ , 8), 275 (16), 257 (22), 235 (100). For $C_{24}H_{19}N_3O_4$ (413.43): C, 69.72; H, 4.63; N, 10.16; found: C, 69.85; H, 4.52; N, 10.07.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

